Sequential combined treatment with intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation

F. Viola, C. Mapelli, E. Villani, F. Tresca Carducci, D. Vezzola, R. Ratiglia

Research output: Contribution to journalArticle

Abstract

Purpose To study visual and anatomical outcomes of sequenced combined therapy using intravitreal bevacizumab followed by photodynamic therapy (PDT) in eyes with retinal angiomatous proliferation (RAP). Safety and rate of intravitreal injections were also evaluated. Methods We conducted a prospective non-comparative pilot study of consecutive patients newly diagnosed with RAP. PDT guided by indocyanine green (ICG) angiography was applied 8±2 days after the intravitreal bevacizumab (1.25 mg) injection. At baseline and every month after the injection, best-corrected visual acuity (BCVA) measurement, complete eye examination including dynamic fluorescein and ICG angiography, and optical coherence tomography (OCT) were performed. Results In all, 21 eyes of 18 patients with RAP were enrolled. The mean age was 77 (range 65-86) years. Mean visual acuity at baseline was 0.63±0.25 logMAR. After treatment BCVA showed no statistically significant differences between each visit (P=0.10, ANOVA). At 9 months, the BCVA improved by three or more lines in three eyes (14%), remained stable in twelve eyes (57%), and worsened in six eyes (29%). Foveal thickness decreased significantly between baseline and all the follow-up visits (P

Original languageEnglish
Pages (from-to)1344-1351
Number of pages8
JournalEye (London, England)
Volume24
Issue number8
DOIs
Publication statusPublished - Aug 2010

Keywords

  • age-related macular degeneration
  • bevacizumab (Avastin)
  • fluorescein angiography
  • ICG angiography
  • PDT
  • RAP

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Sequential combined treatment with intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation'. Together they form a unique fingerprint.

  • Cite this